Lifecore Biomedical, INC \de\

Lifecore Biomedical announced the redemption of all outstanding Series A Redeemable Convertible Preferred Stock, totaling approximately $52.1 million, with a payment deadline of December 28, 2026.

Lifecore Biomedical stockholders approved the 2026 Stock Incentive Plan and elected nine directors at the annual meeting.

Lifecore Biomedical reported a 34% revenue decrease in Q1 2026 compared to the prior year, alongside significant operating expense reductions and reaffirmed full-year guidance.

Lifecore Biomedical reported strong financial results for the fourth quarter and transition period ended December 31, 2025, surpassing revenue guidance and significantly improving margins.

Lifecore Biomedical, Inc. announced a change in its fiscal year to align with the calendar year, impacting its 2026 Annual Meeting and shareholder nomination deadlines.

Lifecore Biomedical, Inc. has adopted an Incentive Bonus Plan for executive officers and employees, effective January 14, 2026, linking cash payments to performance targets.

Lifecore Biomedical reported a significant decrease in total revenues for the first quarter of 2026, driven by lower demand in HA manufacturing and CDMO services.

Lifecore Biomedical, a CDMO and HA manufacturer, reported a 26% increase in total revenues to $31.1 million for the quarter ended September 30, 2025, alongside a reduced net loss.

Lifecore Biomedical's Q3 2025 results reveal a slight revenue decrease and a significant net loss increase, impacted by restructuring, legal expenses, and the loss on the sale of assets.

Lifecore Biomedical's second quarter results show revenue growth offset by increased operating expenses and a net loss, while the company navigates ongoing restructuring and legal issues.

Lifecore Biomedical's first quarter results show a net loss of $16.23 million, impacted by restructuring costs and increased professional fees, despite a rise in gross profit.

Lifecore Biomedical's Q3 2024 results show revenue growth driven by fermentation and CDMO segments, but the company continues to navigate financial and operational challenges.

Lifecore Biomedical, Inc. reports significant revenue and cash flow improvements for its transition period, despite ongoing net losses and internal control weaknesses.

Lifecore Biomedical, Inc. reported a significant net loss for fiscal year 2025, despite progress in strategic initiatives and capacity expansion.

Lifecore Biomedical's 10-K filing reveals a year of revenue growth and improved gross profit, alongside ongoing financial and operational challenges.

Lifecore Biomedical, Inc. has restated its financial statements for fiscal years 2021 and 2022 due to errors in accounting, revealing material weaknesses in internal controls.

Director Christopher S. Kiper of Lifecore Biomedical, Inc. was granted 25,907 restricted stock units as compensation for board service.

Director Nelson Obus has been granted 25,907 restricted stock units, bringing his total beneficial ownership to 164,100 shares.

Director Jason Aryeh acquired 25,907 restricted stock units in Lifecore Biomedical, Inc., increasing his total beneficial ownership to nearly 70,000 shares.

Director Joshua Schechter has been granted 25,907 restricted stock units as part of his compensation, increasing his total beneficial ownership to 133,080 shares.

Director Matthew E. Korenberg has been granted 25,907 restricted stock units, increasing his total stake in Lifecore Biomedical to nearly 70,000 shares.

Lifecore Biomedical Director Humberto Calheiros Antunes has been granted 25,907 restricted stock units as part of director compensation, increasing his total holdings to 72,967 shares.

Lifecore Biomedical, Inc. has filed its 2026 proxy statement, outlining proposals for director elections, auditor ratification, executive compensation, and a new 2026 Stock Incentive Plan.

Lifecore Biomedical, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on October 29, 2025, addressing director elections, auditor ratification, and executive compensation.

Lifecore Biomedical is holding a special meeting of stockholders to approve the issuance of shares underlying Series A Convertible Preferred Stock, aiming to remove a conversion limit and potentially increase the voting power of preferred stockholders.

Lifecore Biomedical plans a special meeting on April 10, 2025, to seek stockholder approval for removing the exchange cap on its Series A Convertible Preferred Stock.

Lifecore Biomedical announces its 2024 Annual Meeting of Stockholders to be held virtually on November 7, 2024, covering director elections, auditor ratification, and executive compensation.

Lifecore Biomedical amends its proxy statement to reflect changes in Delaware law regarding the voting standard for increasing authorized shares and corrects a typographical error in the proposed amendment language.

Lifecore Biomedical is registering the resale of up to 6,795,344 shares of its common stock by selling stockholders following recent private placements.

Legion Partners, through various entities, has increased its beneficial ownership of Lifecore Biomedical, Inc. to 17.1%, signaling a significant investment and potential strategic interest.

22NW Fund has initiated a redemption process for its Series A Preferred Stock in Lifecore Biomedical, signaling a significant shift in its investment.

22NW Fund, LP, a major investor in Lifecore Biomedical, Inc., has reduced its beneficial ownership to 7.49% of the company's common stock after selling over 1.49 million shares in the open market.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in LifeCore Biomedical, Inc., holding 1,899,903 shares of common stock.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 4.9% beneficial ownership in LifeCore Biomedical, Inc. common stock.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.0% beneficial ownership stake in LifeCore Biomedical, Inc.'s common stock.

Greenhaven Road Investment Management, along with affiliated entities, has reported a 9.8% beneficial ownership stake in Lifecore Biomedical, Inc. as of December 31, 2024.

Greenhaven Road Investment Management and its affiliated entities have filed an amended Schedule 13G, reporting a passive beneficial ownership of 7.8% in Lifecore Biomedical, Inc.'s common stock as of December 31, 2023.

David Capital Partners, LLC and David Capital Partners Fund, LP have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.87% in LifeCore Biomedical, Inc. as of December 31, 2024.